A Phase 2 interventional study of lamotrigine in Epilepsy, sponsored by GlaxoSmithKline. Completed at 70 sites in 15 countries. Open to participants aged 1 Month to 24 Months. Per ClinicalTrials.gov, last updated 2017-01-18.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing lamotrigine in Epilepsy — 2 open to participants now, 2 under way, none of them phase 3. Lamotrigine · Epilepsy.
Among the 36 studies testing lamotrigine in Epilepsy, this one is the 8th largest by enrollment, is one of 3 that started in 2000, is one of 2 in phase 2, and was the 4th registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →2 of the 36 studies testing lamotrigine in Epilepsy are open now. Recruiting first, the newest first:
Assiut University
Ages 2–12 · Healthy volunteers
National Taiwan University Hospital
Ages 20+
Lamotrigine: first FDA approval 1994 (LAMICTAL). What it is approved for, and how studies give it, is on its page →
Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 1 Month to 24 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 3 started in 2000.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 197 is above the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 76 across the 36 interventional studies. Of the 32 that completed or were terminated, 14 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 36 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
54 studies in Epilepsy by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 53 finished, 23 (43%) have results posted.
Among the 54 studies in Epilepsy by GlaxoSmithKline, this one is the 9th largest by enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2000, is one of 4 in phase 2, and was the 4th registered.
GlaxoSmithKline’s Epilepsy studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 36 studies testing lamotrigine in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 54 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the long-term safety of LAMICTAL(lamotrigine)in subjects with partial seizures previously enrolled in protocol LAM20006 and in subjects 1-24 months of age who have never received LAMICTAL(LAMICTAL-naive). For LAMICTAL-naive subjects, LAMICTAL will be added to the subject's current epilepsy medications.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Number of participants with overall, serious, drug-related treatment emergent adverse events and adverse events leading to premature study discontinuation
Time frame: 43 Months
Change from baseline in vital signs -heart rate (HR)
Time frame: Up to 43 Months
Change from baseline in vital signs - weight (WT)
Time frame: Up to 43 months
Change from baseline in vital signs - height (HT)
Time frame: Up to 43 months
Change from baseline in vital signs - head circumference (HC)
Time frame: Up to 43 months
Change from baseline in clinical chemistry parameters including Albumin and Total protein
Time frame: Up to month 43
Change from baseline in clinical chemistry parameters including alkaline phosphatase, Alanine transaminase (ALT), and Aspartate Aminotransferase (AST)
Time frame: Up to 43 moths
Change from baseline in clinical chemistry parameters including total bilirubin and creatinine
Time frame: Up to 43 months
Change from baseline in clinical chemistry parameters including glucose (glu), potassium (K), sodium (Na) and urea
Time frame: Up to 43 months
Change from baseline in hematological parameters including bands, basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and total white blood cells (WBC)
Time frame: Up to 43 moths
Change from baseline in Hemoglobin (Hb)
Time frame: Up to 43 months
Change from baseline in Mean corpuscular hemoglobin (MCH)
Time frame: Up to 43 months
Change from baseline in Mean corpuscular hemoglobin concentration (MCHC)
Time frame: Up to 43 months
Change from baseline in mean corpuscular volume (MCv)
Time frame: Up to 43 months
Change from baseline in red blood cells (RBC)
Time frame: Up to 43 months
Number of participants with treatment emergent neurological abnormalities
Time frame: Up to 43 months
Number of participants with treatment emergent clinically significant ECG abnormalities
Time frame: Up to 43 months
Number of participants with potentially clinically significant change in hematology parameters
Time frame: Up to 43 months
Number of participants with potentially clinically significant change in clinical chemistry parameters
Time frame: Up to 43 months
Number of participants with potentially clinically significant change in vital signs
Time frame: Up to 43 months
Mean percentage change in seizure frequency between the Historical Baseline Phase and over the course of the 48-week Treatment Phase
Time frame: Up to 48 Weeks
Investigator's assessment of the participant's overall clinical status
Time frame: Up to 43 months
Mean Maximal plasma concentration (Cmax) in serum and saliva of Lamicital -naïve participants
Time frame: Week 6
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Sep 2000, a primary completion of Jun 2006 and a completion of Jun 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lamotrigine